**ABSTRACT:** Inefficient cellular delivery limits the landscape of macromolecular drugs. Boronic acids readily form boronate esters with the 1,2- and 1,3-diols of saccharides, such as those that coat the surface of mammalian cells. Here pendant boronic acids are shown to enhance the cytosolic delivery of a protein toxin. Thus, boronates are a noncationic carrier that can deliver a polar macromolecule into mammalian cells.

The utility of many biologic drugs is limited by inefficient cellular delivery. Previous efforts to overcome this limitation have focused largely on the use of cationic domains—peptidic (e.g., HIV-TAT, penetratin, and nona-arginine) or nonpeptidic (e.g., PAMAM dendrimers and polyethylenimine)—to enhance the attraction between a chemotherapeutic agent and the anionic cell surface. Natural ligands (e.g., folic acid, substance P, and the RGD tripeptide) have also been used to facilitate cellular delivery by targeting agents to specific cell-surface receptors. Although these methods have achieved some success, additional delivery strategies are desirable.

The cell surface is coated with a dense forest of polysaccharides known as the glycocalyx. We anticipated that targeting therapeutic agents to the glycocalyx would enhance their cellular delivery, as has been demonstrated with lectin conjugates. Boronic acids readily form boronate esters with the 1,2- and 1,3-diols of saccharides, including those in the glycocalyx. In addition, boronate groups are compatible with human physiology, appearing in chemotherapeutic agents and other remedies. Further, pendant boronic acids conjugated to polyethyleneimine have been shown to enhance DNA transfection. Here we demonstrate the use of pendant boronic acids to mediate the delivery of a protein into the cytosol of mammalian cells.

Bovine pancreatic ribonuclease (RNase A) is a small, well-characterized enzyme that has been the object of much seminal work in protein chemistry. If this ribonuclease can gain access to the RNA that resides in the cytosol, then its prodigious catalytic activity can lead to cell death. Hence, RNase A can serve as an ideal model for assessing the delivery of a protein into the cytosol (rather than an endosome) because success can be discerned with assays of cytotoxic activity.

Initially, we quantified the affinity of simple boronic acids to relevant saccharides. Sialic acid is of particular interest because of its abundance in the glycocalyx of cancer cells. Phenylboronic acid (PBA) binds with higher affinity to sialic acid than to other pyranose saccharides, suggesting that simple boronic acids could target chemotherapeutic agents selectively to tumors. 2-Hydroxymethylphenylboronic acid (benzoxaborole) has the highest reported affinity for pyranose saccharides, which are abundant in the glycocalyx; hence, we reasoned that benzoxaborole could be an ideal boronate for drug delivery. We used 1H NMR spectroscopy to evaluate directly the affinity of PBA and benzoxaborole for fructose, glucose, and N-acetyleneuraminic acid (Neu5Ac), which contains a sialic acid moiety, under physiological conditions. Our $K_a$ values (Table 1) are in accord with values determined by other workers using competition and other assays (Table S1 in the Supporting Information). We found that benzoxaborole has a greater affinity than PBA for each saccharide in our panel and that benzoxaborole, like PBA, has a greater affinity for Neu5Ac than for glucose. Accordingly, we chose benzoxaborole for our boronate-mediated delivery studies.

To display benzoxaborole moieties on RNase A, we conjugated 5-amino-2-hydroxymethylphenylboronic acid to protein carboxyl groups by condensation using a carbodiimide (Figure 1). Of the 11 carboxyl groups of RNase A, 7.5 ± 2.0 were condensed with boronate groups. After benzoxaborole conjugation, RNase A was shown to be expressed as a protein toxin and to mediate delivery into mammalian cells.

**Table 1. Values of $K_a$ (M$^{-1}$) for Boronic Acids and Saccharides**

| Saccharide | $K_a$ (M$^{-1}$) |
|------------|-----------------|
| d-fructose | 128 ± 20        |
| d-glucose | 5 ± 1           |
| Neu5Ac    | 13 ± 1          |

Each value is the mean ± standard deviation (SD) for ≥15 measurements in 0.10 M sodium phosphate buffer (pH 7.4) containing 2% (v/v) D$_2$O.

**Received:** November 14, 2011  
**Published:** February 3, 2012
measured the retention of boronated and unmodified RNase A on a column of heparin, a common physiological polysaccharide. Boronated RNase A was indeed retained longer on the column (Figure 2). If the prolonged retention were due to boron–saccharide complexation, then fructose in the buffer should compete with immobilized heparin for boron complexation. When these conditions were employed, the retention of boronated RNase A was indeed diminished (Figure 2).

To evaluate the enhanced affinity of boronated RNase A for oligosaccharides, we measured its affinity for ganglioside GD3 within a 1,2-dioleoyl-sn-glycero-3-phosphocholine liposome. This ganglioside has two sialic acid residues and is overexpressed on the surface of cancer cells. By using fluorescence polarization to analyze binding, we found that boronation increased the affinity of the protein for the ganglioside, an effect that was abrogated by fructose (Figure 3). The $K_d$ value of boronated protein for GD3 ganglioside liposomes was $(53 \pm 11) \mu M$. This affinity is $\sim 440$-fold greater than that for the binding of a single benzoxaborole to Neu5Ac (Table 1), consistent with a multivalent interaction between the boronated protein and the ganglioside.

Encouraged by the enhanced affinity of the boronated protein for oligosaccharides in vitro, we sought to test our hypothesis that boronate conjugation increases cellular uptake. To quantify cellular internalization, we used a fluorophore-labeled protein and flow cytometry. To determine concurrently whether the pendant boronates would elicit selectivity for cells with higher quantities of cell-surface sialic acid, we employed a line of Chinese hamster ovary cells (Lec-2) that have lower levels of sialic acid in their glycocalyx than their progenitor line (Pro-5). We found that boronation of RNase A increased its cellular uptake by 4–5-fold (Figure 4). This enhancement was eliminated by fructose. Cell-surface sialic acid content did not affect uptake significantly, consistent with the modest (1.5-fold) increase in the $K_a$ value for benzoxaborole with sialic acid versus glucose (Table 1). Confocal microscopy of the boronated protein revealed punctate staining (Figure 4 inset), which is consistent with uptake by endocytosis following complexation with cell-surface saccharides.

Although flow cytometry can quantify protein internalization into a cell, it does not differentiate between proteins in endosomes versus those in the cytosol. Delivery into the...
cytosol is essential for the efficacy of numerous putative chemotherapeutic agents. Boronated RNase A retained 17% of its ribonucleolytic activity.\(^\text{19}\) Accordingly, boronated RNase A has the potential to be cytotoxic if it can gain entry to the cytosol. We found that boronated RNase A inhibited the proliferation of human erythroleukemia cells (Figure 5). The addition of fructose diminished the cytotoxic activity, presumably by decreasing the overall internalization. Chemically inactivated boronated RNase A was much less cytotoxic, indicating that the ribonucleolytic activity induced toxicity, not the pendant boronates. We conclude that boronation not only facilitates cellular uptake of a protein but also enhances its delivery to the cytosol.

Boronates have attributes that make them attractive as mediators of drug delivery. First, endosomes become more acidic as they mature. In synergy, the affinity of boronates for particular glycans could serve as the basis for targeted delivery strategies.\(^\text{24}\) These attributes could facilitate translocation to the cytosol. Second, boronates are not cationic,\(^\text{21}\) avertin the nonspecific Coulombic interactions elicited by cationic domains,\(^\text{22}\) which can lead to high rates of glomerular filtration and opsonization in vivo.\(^\text{23}\) Finally, we note that numerous diseases are associated with changes in cell-surface glycosylation,\(^\text{12,23}\) and we anticipate that boronic acids with specificity for particular glycans could serve as the basis for targeted delivery strategies.

**ACKNOWLEDGMENTS**

M.J.P. was supported by Molecular and Cellular Pharmacology Training Grant T32 GM008688 (NIH) and Predoctoral Fellowship 09PRE2260125 (American Heart Association). This work was supported by Grants R01 GM044783 and R01 CA073808 (NIH).

**REFERENCES**

1. (a) Patil, S. D.; Rhodes, D. G.; Burgess, D. J. AAPs J. 2005, 7, E61–E77. (b) Malik, D. K.; Baboota, S.; Ahuja, A.; Hasan, S.; Ali, J. Curr. Drug Delivery 2007, 4, 141–151. (c) Shim, M. S.; Kwon, Y. J. FEBS J. 2010, 277, 4814–4827.
2. (a) Gao, Y.; Gao, G.; He, Y.; Liu, T.; Qi, R. Mini-Rev. Med. Chem. 2008, 8, 889–900. (b) Rapoport, M.; Lorberboum-Galski, H. Expert Opin. Drug Delivery 2009, 6, 453–63. (c) Sun, X.; Zhang, N. Mini-Rev. Med. Chem. 2010, 10, 108–125. (d) Schmidt, N.; Mishra, A.; Lai, G. H.; Wong, G. C. FEBS Lett. 2010, 584, 1806–1813.
3. (a) Zhao, X.; Li; H.; Lee, R. J. Expert Opin. Drug Delivery 2008, 5, 309–319. (b) Rizk, S. S.; Luchniak, A.; Uysal, S.; Crawley, C. M.; Rock, R. S.; Kossiakoff, A. A. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 11011–11015. (c) Mohanty, C.; Das, M.; Kanwar, J. R.; Sahoo, S. K. Curr. Drug Delivery 2011, 8, 45–58.
4. (a) Varki, A.; Cummins, R. D.; Esko, J. D.; Freeze, H. H.; Stanley, P.; Bertozi, C. R.; Hart, G. W. Essentials of Glycobiology, 2nd ed.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2009.
5. (a) Ishiguro, M.; Hisako, T.; Sakakibara, R.; Yamaguchi, J.; Aso, Y. J. Fac. Agric. Kyushu Univ. 2002, 46, 367–379.
6. (a) James, T. D.; Phillips, M. D.; Shinkai, S. Boronic Acids in Saccharide Recognition; Royal Society of Chemistry: Cambridge, U.K., 2006.
7. (a) Vandenburg, Y. R.; Zhang, Z. Y.; Fishkind, D. J.; Smith, B. D. Chem. Commun. 2000, 149–150. (b) Yang, W.; Fan, H.; Gao, X.; Gao, S.; Kamati, V. V.; Ni, W.; Hooks, W. B.; Carsson, J.; Weston, B.; Wang, B. Chem. Biol. 2004, 11, 439–448. (c) Polsky, R.; Harper, J. C.; Wheeler, D. R.; Arango, D. C.; Brozik, S. M. Angew. Chem. 2008, 120, 2671–2674. (d) Matsumoto, A.; Sato, N.; Kataoka, K; Miyahara, Y. J. Am. Chem. Soc. 2009, 131, 12002–12203. (e) Zhong, X.; Bai, H. J.; Xu, J. J.; Chen, H. Y.; Zhu, Y. H. Adv. Funct. Mater. 2010, 20, 992–999.
8. (a) Matsumoto, A.; Cabral, H.; Sato, N.; Kataoka, K; Miyahara, Y. Angew. Chem. Int. Ed. 2010, 49, 5494–5497.
9. (a) Westmark, P. R.; Smith, B. D. J. Pharm. Sci. 1996, 85, 266–269. (b) Jay, J. I.; Lai, B. E.; Myszka, D. G.; Mahalingam, A.; Langeheinrich, K.; Katz, D. F.; Kiser, P. F. Mol. Pharmacol. 2009, 7, 116–129. (c) Barth, R. F. Appl. Radiat. Isot. 2009, 67, S3–S6. (d) Wu, W.; Mitra, N.; Yan, E. C.; Zhou, S. ACS Nano 2010, 4, 4831–4839. (e) Kumar, A.; Hozo, I.; Wheatley, K.; Djublevicog, B. Am. J. Hematol. 2011, 86, 18–24.
10. (a) Fung, Q.; Chen, F.; Zhong, Z.; Zhuo, R. Curr. Drug. 2010, 46, 5888–5890.
11. (a) Rabinowic: Structures and Functions; D’Alessio, G., Birodd, J. F., Eds.; Academic Press: New York, 1997. (b) Raines, R. T. Chem. Rev. 1998, 98, 1045–1065. (c) Marshall, G. R.; Feng, J. A.; Kuster, D. J. Biopolymers 2008, 90, 259–277. (d) Chuilho, C. M.; Nogues, M. V.; Raines, R. T. Biochemistry 2011, 50, 7835–7841.
12. (a) Leland, P. A.; Raines, R. T. Chem. Biol. 2001, 8, 405–413. (b) Futami, J.; Maeda, T.; Kitazoe, M.; Nuki, E.; Tada, H.; Seno, M.; Kosaka, M.; Yamada, H. Biochemistry 2001, 40, 7518–7524. (c) Futami, J.; Nuki, K.; Maeda, T.; Kosaka, M.; Tada, H.; Seno, M.; Yamada, H. J. Biochem. (Tokyo) 2002, 132, 223–228. (d) Rutkoski, T. J.; Kurten, E. L.; Mitchell, J. C.; Raines, R. T. J. Mol. Biol. 2005, 354, 41–54. (e) Futami, J.; Kitazoe, M.; Maeda, T.; Nuki, E.; Sakaguchi, M.; Kosaka, J.; Miyazaki, M.; Kosaka, M.; Tada, H.; Seno, M; Sasaki, J.; Huh, N. H.; Namba, M.; Yamada, H. J. Biosci. Bioeng. 2005, 99, 95–103. (f) Rutkoski, T. J.; Raines, R. T. Curr. Pharm. Biotechnol. 2008, 9, 185–189.

**ASSOCIATED CONTENT**

\(\text{Supporting Information}\)

Analytical data and experimental protocols. This material is available free of charge via the Internet at http://pubs.acs.org.

**AUTHOR INFORMATION**

**Corresponding Author**

rtraines@wisc.edu

**Author Contributions**

\(^\text{2}\) These authors contributed equally.
(12) Dube, D. H.; Bertozzi, C. R. *Nat. Rev. Drug Discovery* **2005**, *4*, 477–488.

(13) (a) Springsteen, G.; Wang, B. *Tetrahedron* **2002**, *58*, 5291–5300. (b) Otsuka, H.; Uchimura, E.; Koshino, H.; Okano, T.; Kataoka, K. *J. Am. Chem. Soc.* **2003**, *125*, 5493–5502. (c) Djanashvili, K.; Frullano, L.; Peters, J. A. Chem.—*Eur. J.* **2005**, *11*, 4010–4018.

(14) (a) Torssell, K. Ark. Kemi **1957**, *10*, 507–511. (b) Snyder, H. R.; Reed, A. J.; Lennarz, W. J. *J. Am. Chem. Soc.* **1958**, *80*, 835–838. (c) Adamczyk-Woźniak, A.; Cyrański, M. K.; Zubrowska, A.; Sporzyński, A. J. *Organomet. Chem.* **2009**, *694*, 3533–3541.

(15) (a) Dowlut, M.; Dennis, G. *J. Am. Chem. Soc.* **2006**, *128*, 4226–4227. (b) Bérubé, M.; Dowlut, M.; Hall, D. G. *J. Org. Chem.* **2008**, *73*, 6471–6479.

(16) Wlodawer, A.; Svensson, L. A.; Sjölin, L.; Gilliland, G. L. *Biochemistry* **1988**, *27*, 2705–2717.

(17) Malisan, F.; Testi, R. *IUBMB Life* **2005**, *57*, 477–482.

(18) Deutscher, S. L.; Nuwayhid, N.; Stanley, P.; Briles, E. L.; Hirschberg, C. B. *Cell* **1984**, *39*, 295–299.

(19) The lost activity is attributable, at least in part, to the modification of the carboxyl group of aspartic acid 121, which is known to contribute to catalysis. See: Schultz, L. W.; Quirk, D. J.; Raines, R. T. *Biochemistry* **1998**, *37*, 8886–8898.

(20) Mothana, S.; Grassot, J. M.; Hall, D. G. *Angew. Chem., Int. Ed.* **2010**, *49*, 2883–2887.

(21) The HOB of benzoxaborole has pK_a = 7.34 ± 0.02 (see: Tomsho, J. W.; Pal, A.; Hall, D. G.; Benkovic, S. J. *ACS Med. Chem. Lett.* **2012**, *2*, 48–52), preserving most of the anionicity of a typical carboxyl group at pH 7.4.

(22) (a) Venturoli, D.; Rippe, B. *Am. J. Physiol.: Renal, Fluid Electrolyte Physiol.* **2005**, *288*, F605. (b) Owens, D. E.; Peppas, N. A. *Int. J. Pharm.* **2006**, *307*, 93–102.

(23) Cheng, Y. F.; Li, M. Y.; Wang, S. R.; Peng, H. J.; Reid, S.; Ni, N. T.; Fang, H.; Xu, W. F.; Wang, B. H. *Sci. China: Chem.* **2010**, *53*, 3–20.

(24) Pal, A.; Bérubé, M.; Hall, D. G. *Angew. Chem., Int. Ed.* **2010**, *49*, 1492–1495.